Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy
Authors
Keywords
-
Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 42, Issue 4, Pages 391-405
Publisher
Wiley
Online
2015-06-15
DOI
10.1111/apt.13276
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
- (2015) Konstantinos Papamichael et al. Clinical Gastroenterology and Hepatology
- Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease
- (2015) Ivan Guerra et al. CURRENT DRUG METABOLISM
- Effectiveness of Adalimumab in Perianal Fistulas in Crohn’s Disease Patients Naive to Anti-TNF Therapy
- (2015) Carlos Castaño-Milla et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases
- (2014) B. Pariente et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Postoperative Therapy With Infliximab Prevents Long-term Crohn’s Disease Recurrence
- (2014) Miguel Regueiro et al. Clinical Gastroenterology and Hepatology
- Early Trough Levels and Antibodies to Infliximab Predict Safety and Success of Reinitiation of Infliximab Therapy
- (2014) Filip Baert et al. Clinical Gastroenterology and Hepatology
- Assessment of the Influence of Inflammation and FCGR3A Genotype on Infliximab Pharmacokinetics and Time to Relapse in Patients with Crohn’s Disease
- (2014) David Ternant et al. CLINICAL PHARMACOKINETICS
- Infliximab as a bridge to remission maintained by antimetabolite therapy in Crohn's disease: A retrospective study
- (2014) Armelle Chauvin et al. DIGESTIVE AND LIVER DISEASE
- How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?
- (2014) María Chaparro et al. Expert Opinion On Drug Safety
- Stopping Anti-TNF Agents in Patients with Crohnʼs Disease in Remission
- (2014) Dario Sorrentino et al. INFLAMMATORY BOWEL DISEASES
- Smoking in inflammatory bowel disease: Impact on disease course and insights into the aetiology of its effect
- (2014) Gareth C. Parkes et al. Journal of Crohns & Colitis
- Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission
- (2014) Masao Nawata et al. Modern Rheumatology
- Mucosal Healing Did Not Predict Sustained Clinical Remission in Patients with IBD after Discontinuation of One-Year Infliximab Therapy
- (2014) Cong Dai et al. PLoS One
- Frequency and prognostic role of mucosal healing in patients with Crohn’s disease and ulcerative colitis after one-year of biological therapy
- (2014) Klaudia Farkas WORLD JOURNAL OF GASTROENTEROLOGY
- Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era
- (2013) T. Nunes et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Safety of Anti-TNF Agents During Pregnancy and Breastfeeding in Women With Inflammatory Bowel Disease
- (2013) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
- (2013) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Optimizing anti-TNF treatments in inflammatory bowel disease
- (2013) Shomron Ben-Horin et al. AUTOIMMUNITY REVIEWS
- Pouchitis: What Every Gastroenterologist Needs to Know
- (2013) Bo Shen Clinical Gastroenterology and Hepatology
- A prospective study of infliximab withdrawal after 12 months of treatment in patients with Crohn's disease: how will NICE guidance affect patient care?
- (2013) L. Blackmore et al. CLINICAL MEDICINE
- P.02.11 WITHDRAWAL OF INFLIXIMAB (IFX) AFTER ACHIEVING REMISSION: OUTCOME IN A COHORT OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
- (2013) I. Luppino et al. DIGESTIVE AND LIVER DISEASE
- Management of Postoperative Recurrence of Crohn's Disease
- (2013) Anja U. van Lent et al. DIGESTIVE DISEASES
- Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring
- (2013) Jose-Manuel Benitez et al. GUT
- Ten Years of Infliximab for Crohn’s Disease
- (2013) Emma J. Eshuis et al. INFLAMMATORY BOWEL DISEASES
- P392 Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study
- (2013) S. Sebastian et al. Journal of Crohns & Colitis
- Long term benefit of one year infliximab administration for the treatment of chronic refractory pouchitis
- (2013) Nikos Viazis et al. Journal of Crohns & Colitis
- When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel
- (2013) Valerie Pittet et al. Journal of Crohns & Colitis
- Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III)
- (2013) Fernando Magro et al. Journal of Crohns & Colitis
- Predictors for developing intestinal failure in patients with Crohn's disease
- (2013) Richard B Gearry et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy
- (2013) Klaudia Farkas et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Normalization of mucosal cytokine gene expression levels predicts long-term remission after discontinuation of anti-TNF therapy in Crohn's disease
- (2013) Renathe Rismo et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
- (2012) T. Molnár et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Discontinuing Anti–Tumor Necrosis Factor Therapy During Pregnancy on the Course of Inflammatory Bowel Disease and Neonatal Exposure
- (2012) Zuzana Zelinkova et al. Clinical Gastroenterology and Hepatology
- Transplacental Transfer of Immunosuppressants and Biologics Used for the Treatment of Inflammatory Bowel Disease
- (2012) Maria Chaparro et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies
- (2012) Ren Mao et al. INFLAMMATORY BOWEL DISEASES
- Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease
- (2012) Alessandro Armuzzi et al. Journal of Crohns & Colitis
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
- (2012) Filip Baert et al. Journal of Crohns & Colitis
- Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study
- (2012) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Crohn’s disease genotypes of patients in remissionvsrelapses after infliximab discontinuation
- (2012) Cathy Lu WORLD JOURNAL OF GASTROENTEROLOGY
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapy
- (2011) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
- (2011) Edouard Louis et al. GASTROENTEROLOGY
- Long-term outcome of treatment with infliximab in pediatric-onset Crohnʼs disease: A population-based study
- (2011) Valérie Crombé et al. INFLAMMATORY BOWEL DISEASES
- Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission
- (2011) Kofi Clarke et al. INFLAMMATORY BOWEL DISEASES
- Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults
- (2010) J. LINDSAY et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Maintenance of clinical benefit in Crohn’s disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
- (2010) A. W. G. Waugh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD With the European Crohn's and Colitis Organization: When to Start, When to Stop, Which Drug to Choose and How to Predict Response?
- (2010) Geert R D'Haens et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
- (2010) Y. Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Long-Term Monitoring of Infliximab Therapy for Perianal Fistulizing Crohn's Disease by Using Magnetic Resonance Imaging
- (2010) Konstantinos Karmiris et al. Clinical Gastroenterology and Hepatology
- Anti-TNF and Crohns Disease: When Should We Stop?
- (2010) Edouard Louis et al. CURRENT DRUG TARGETS
- CO12 LONG TERM EFFICACY OF INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE AT A SINGLE TERTIARY CENTER
- (2010) F. Nuti et al. DIGESTIVE AND LIVER DISEASE
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
- (2009) Filip Baert et al. GASTROENTEROLOGY
- Management and prevention of postoperative Crohnʼs disease
- (2009) Miguel Regueiro INFLAMMATORY BOWEL DISEASES
- Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohnʼs disease
- (2009) Fabian Schnitzler et al. INFLAMMATORY BOWEL DISEASES
- Infliximab Reintroduction is Not Associated to a Higher Rate of Immune-related Adverse Effects in Patients With Inflammatory Bowel Disease Initially Treated With a Three-infusion Induction Regimen
- (2009) Eugeni Domènech et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- 12-Month Follow-up After Successful Infliximab Therapy in Pediatric Crohn Disease
- (2009) Jan Wynands et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Clinical implications of mucosal healing for the management of IBD
- (2009) Guillaume Pineton de Chambrun et al. Nature Reviews Gastroenterology & Hepatology
- Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease
- (2008) J.P. Gisbert et al. DIGESTIVE AND LIVER DISEASE
- Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
- (2008) Miguel Regueiro et al. GASTROENTEROLOGY
- Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?
- (2008) T. Molnár et al. Journal of Crohns & Colitis
- Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experience
- (2008) L. Guidi et al. Techniques in Coloproctology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now